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Vaccinia virus (VV) has manymechanisms to suppress
and modulate the host immune response. The VV pro-
tein A52R was previously shown to act as an intracellu-
lar inhibitor of nuclear factor B (NFB) signaling by
Toll-like receptors (TLRs). Co-immunoprecipitation
studies revealed that A52R interacted with both tumor
necrosis factor receptor-associated factor 6 (TRAF6)
and interleukin-1 receptor-associated kinase 2 (IRAK2).
The effect of A52R on signals other than NFB was not
determined. Here, we show that A52R does not inhibit
TLR-induced p38 or c-Jun amino N-terminal kinase
(JNK) mitogen activating protein (MAP) kinase activa-
tion. Rather, A52R could drive activation of these ki-
nases. Two lines of evidence suggested that the A52R/
TRAF6 interaction was critical for these effects. First,
A52R-induced p38 MAP kinase activation was inhibited
by overexpression of the TRAF domain of TRAF6, which
sequestered A52R and inhibited its interaction with en-
dogenous TRAF6. Second, a truncated version of A52R,
which interacted with IRAK2 and not TRAF6, was un-
able to activate p38. Because interleukin 10 (IL-10) pro-
duction is strongly p38-dependent, we examined the ef-
fect of A52R on IL-10 gene induction. A52R was found to
be capable of inducing the IL-10 promoter through a
TRAF6-dependent mechanism. Furthermore, A52R en-
hanced lipopolysaccharide/TLR4-induced IL-10 produc-
tion, while inhibiting the TLR-induced NFB-dependent
genes IL-8 andRANTES. These results show that although
A52R inhibits NFB activation by multiple TLRs it can
simultaneously activate MAP kinases. A52R-mediated en-
hancement of TLR-induced IL-10 may be important to
virulence, given the role of IL-10 in immunoregulation.
The recently described Toll-like receptor (TLR)1 family are
critical in initiating an appropriate innate immune response to
infectious agents, and in directing the later adaptive response.
To date, 13 members of the TLR family have been identified in
mammals. The TLRs belong to a superfamily that includes the
interleukin 1 (IL-1) receptors. This family share significant
homology in their cytoplasmic regions, which is defined by the
presence of a Toll-IL-1 receptor-resistance domain (TIR) (1).
Similar to the IL-1R, engagement of the TLRs with their
ligands leads to activation of several intracellular signal trans-
duction pathways, culminating in the induction of proinflam-
matory cytokines such as IL-1 and tumor necrosis factor (TNF),
of chemokines such as IL-8 and RANTES (2), and of the immu-
noregulatory cytokine IL-10 (3). Among the most prominent
and best characterized of these intracellular signaling path-
ways are those leading to the activation of mitogen-activated
protein (MAP) kinases and the transcription factor NFB. Trig-
gering of the IL-1R or of TLRs causes TIR adaptor molecules to
be recruited to the receptor complex such as MyD88 (4) and TIR
domain containing adaptor inducing interferon- (TRIF) (5, 6).
Subsequently, the IL-1 receptor-associated kinases (IRAKs)
such as IRAK1, IRAK2, and IRAK4 are activated, which then
engage with TRAF6, ultimately activating the IB kinase com-
plex. This complex phosphorylates the inhibitory molecule IB,
which leads to NFB entering the nucleus and inducing target
gene expression (7). Activation of TRAF6 also results in the
activation of TAK1 and subsequent activation of MAP kinases
(p42/p44, p38, and JNK).
The TLR family is now known to be important in sensing and
responding to viruses. Double-stranded RNA is a molecular
pattern associated with viral infection, and TLR3 has been
shown to sensitize cells to activation by poly(I:C) a synthetic
double-stranded RNA analogue (8). Other TLRs involved in
sensing viral infection include TLR7 and TLR8, which detect
single-stranded RNA from influenza, human immunodefi-
ciency virus, and vesicular stomatitis virus (9–11), and TLR9,
which recognizes genomic DNA of herpes simplex virus-2 (10,
12). Further evidence for a role for TLRs in responding to
viruses comes from the fact that proteins from VV have been
identified that can block TLR function (13–16). The VV genome
contains numerous genes encoding proteins involved in immu-
nomodulation and immunoevasion. For example, the virus en-
codes proteins that act as decoy receptors for IL-1, IL-18, and
TNF (17). VV is a member of the Poxviridae, a family of com-
plex DNA viruses that replicate in the cytoplasm of vertebrate
and invertebrate cells. The most notorious member, variola
virus, causes smallpox. This disease was eradicated using pro-
phylactic inoculations with the antigenically related VV (18).
One VV protein implicated in the evasion of the host TLR
response is A52R. A role for A52R in VV virulence has been
clearly established in that deletion of a52r from VV led to an
attenuated virus in a murine intranasal infection (15). A52R
was shown to be capable of interacting with IRAK2 and TRAF6
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and to block every IL-1R-TLR pathway to NFB activation
tested (13, 15). However, the effect of A52R on signals other
than NFB has not been determined. Given that many viral
proteins have multiple activities and that other intracellular
effects of A52R might contribute to its role in virulence, we
tested the effect of A52R on signals other than NFB. Here we
show that A52R can activate the MAP kinases p38 and JNK in
a TRAF6-dependent manner. In addition, A52R leads to en-
hancement of the TLR-induced p38-dependent gene IL-10. In
contrast, inhibition of the TLR-induced NFB-dependent genes
IL-8 and RANTES is observed. These results highlight the
ability of A52R to differentially modulate TLR signaling. This
ability of A52R to activate p38 and potentiate TLR-induced
IL-10 may be important to its role in virulence.
MATERIALS AND METHODS
Expression and Reporter Plasmids—CD4-TLR4 was a kind gift from
R. Medzhitov (Yale University, New Haven, CT), and TLR3 was kindly
provided by D. Golenbock (University of Massachusetts Medical School,
Worcester, MA). Myc-IRAK2 was a gift from M. Muzio (19). The TRAF6
expression plasmids, FLAG-TRAF6 and FLAG-TRAF domain
(TRAF6, amino acids 289–522), were provided by Tularik Inc. (San
Francisco, CA). A52R expression plasmid was previously described (13).
A52R was generated by PCR of the A52R plasmid and comprised
amino acids 1–144 of the wild type protein (which is 190 amino acids in
length), plus an extra 27 amino acids derived from the vector sequence.
The NFB luciferase reporter construct was a gift from R. Hofmeister
(University of Regensburg, Germany). The human IL-10 promoter re-
porter plasmid was a kind gift from L. Ziegler-Heitbrock (20).
Antibodies and Reagents—Anti-FLAG M2 monoclonal antibody and
anti-Myc monoclonal antibody clone 9E10 were purchased from Sigma.
Anti-A52R antibody was previously described (15). Anti-IB antibody
was provided by R. Hay (University of St. Andrews, Scotland). Other
antibodies used were anti-TRAF6 (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA), anti-phospho-p38 MAP kinase (Thr180/Tyr182) anti-
body and anti-p38 MAP kinase antibody (both from Cell Signaling
Technology, Beverly, MA), and anti-rabbit IgG antibody-F(ab)2 frag-
ment (Abcam, Cambridge, United Kingdom).
Human rIL-1 was from the National Cancer Institute (Frederick,
MD). The synthetic double-stranded RNA analogue, poly(I:C), was pur-
chased from Amersham Biosciences (Bucks, UK). Lipopolysaccharide
from Escherichia coli serotype EH100(Ra) and the p38 MAP kinase
inhibitor SB203580 were purchased from Alexis Biochemicals (Bing-
ham, Nottingham, UK).
Reporter Gene Assays—HEK 293 cells (2  104 cells per well) were
seeded into 96-well plates and transfected 24 h later with expression
vectors and the indicated luciferase reporter genes using GeneJuiceTM
(Novagen) according to the manufacturer’s instructions. In all cases,
20 ng/well of phRL-TK reporter gene (Promega) was co-transfected to
normalize the data for transfection efficiency. The total amount of DNA
per transfection was kept constant at 230 ng by addition of pcDNA3.1
(Stratagene). For NFB assays, 60 ng of a NFB luciferase reporter
gene was used (15). For IL-10 promoter assays, 60 ng of the IL-10
promoter luciferase reporter gene was used. For MAP kinase reporter
assays the PathDetect SystemTM (Stratagene) was used, whereby either
0.25 ng of a c-Jun-Gal4 (to assay JNK) or a CHOP-Gal4 (to assay p38
MAP kinase) fusion vector was used in combination with 60 ng of
pFR-luciferase reporter. Cells were stimulated with 100 ng/ml IL-1,
1 g/ml LPS, or 25 g/ml poly(I:C), where indicated 6 h prior to har-
vesting. After 24 h, reporter gene activity was measured (15). Data are
expressed as mean -fold induction  S.D. relative to control levels, for
a representative experiment from a minimum of three separate exper-
iments, each preformed in triplicate.
Immunoprecipitation and Immunoblotting—HEK 293T cells (1.5 
106) were seeded into 10-cm dishes 24 h prior to transfection. Transfec-
tions were carried out using GeneJuiceTM. For coimmunoprecipitations,
4 g of each construct were transfected. Where only one construct was
transfected the total amount of DNA (8 g) was kept constant by supple-
mentation with pcDNA3.1. Cells were harvested 24 h post-transfection,
washed twice in phosphate-buffered saline, and lysed in 850 l of lysis
buffer (50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% (v/v)
glycerol, 0.5% (v/v) Nonidet P-40 containing 1 mM phenylmethylsulfonyl
fluoride, 0.01% (v/v) aprotinin, and 1 mM sodium orthovanadate). For
immunoprecipitation, the indicated antibodies were precoupled to either
protein A-Sepharose (polyclonal and FLAG monoclonal antibodies) or
protein G-Sepharose beads (all other monoclonal antibodies) overnight at
4 °C. The beads were then washed twice in lysis buffer and incubated with
the cell lysates overnight at 4 °C. The immune complexes were washed,
boiled with 30 l of 3 sample buffer (62.5 mM Tris, 2% (w/v) SDS, 10%
v/v glycerol, 0.1% (w/v) bromphenol blue), and analyzed using standard
SDS-PAGE and Western blotting techniques.
For analysis of p38 MAP kinase activation by Western blot, a specific
antibody raised against phosphorylated p38 (Thr180/Tyr182) was em-
ployed. Total levels of p38 MAP kinase protein were also analyzed using
anti-p38 MAP kinase antibody. HEK 293 cells (1  105 cells per well)
were seeded into 6-well plates and transfected 24 h later with TRAF6
or A52R encoding plasmids as indicated, using GeneJuiceTM. The total
amount of DNA (2.3 g) was kept constant by supplementation with
pcDNA3.1. 24 h after transfection, cells were lysed in 100 l of SDS
sample buffer (62.5 mM Tris (pH 6.8), 2% (w/v) SDS, 50 mM dithiothre-
itol, 10% glycerol, 0.1% bromphenol blue). Lysates were then resolved
by SDS-PAGE, transferred to poly(vinylidene difluoride) membranes,
and probed with the indicated antibodies according to the manufactur-
er’s instructions.
Determination of Cytokine Concentrations—HEK 293 clonal cell lines
stably expressing either TLR4/MD-2 (HEK-TLR4) or TLR3 (HEK-
TLR3) (21) or the murine macrophage cell line RAW 264.7 were used for
determination of cytokine production. Cells (2  104 cell per well) were
seeded into 96-well plates and transfected 24 h later with an expression
plasmid encoding A52R, TRAF6, or TRAF6 using GeneJuiceTM where
indicated. 24 h after transfection, cells were stimulated with 1 g/ml
LPS or 25 g/ml poly(I:C). 2 h prior to stimulation the p38 MAP kinase
inhibitor SB203580 was added were indicated. After 24 h supernatants
were harvested, and IL-8, RANTES, or IL-10 concentrations were de-
termined by enzyme-linked immunosorbent assay (R&D Biosystems).
Experiments were performed three times in triplicate, and data are
expressed as mean  S.D. from one representative experiment.
RESULTS
A52R Drives p38 MAP Kinase Activation—We previously
showed that deletion of the vaccinia virus a52r gene reduced
virus virulence in a murine intranasal infection model, that
A52R acts as a potent inhibitor of NFB activation induced by
IL-1 and various TLRs, and that it was capable of interacting
with both TRAF6 and IRAK2 (15). However, the effect of A52R
on signals other than NFB was not determined and thus there
might be other functions of A52R that also contribute to viru-
lence. Therefore, here we examined the effect of A52R on p38
MAP kinase activation. For this we used the Stratagene Path-
DetectTM System that is based on the ability of p38 MAP kinase
to phosphorylate and activate the transcription factor CHOP.
This is assayed by an increase in the ability of the Gal4-CHOP
fusion protein to transactivate the pFR luciferase reporter,
which contains Gal4 binding sites in its promoter. Fig. 1A
shows that treatment of cells with IL-1, ectopic expression of
CD4-TLR4, or ectopic expression of TLR3 together with
poly(I:C) stimulation led to activation of p38 MAP kinase. Sur-
prisingly, ectopic expression of increasing amounts of a plasmid
encoding A52R enhanced IL-1-, CD4-TLR4-, and TLR3-medi-
ated p38 MAP kinase activation (Fig. 1A). This was in contrast
to the inhibitory effect of A52R on IL-1/TLR-induced NFB
activation (Fig. 1B and Refs. 13 and 15). In fact, expression of
A52R alone in unstimulated cells led to both p38 MAP kinase
and JNK activation (Fig. 1C), whereas A52R alone had no
effect on basal levels of NFB activity (not shown). Thus, A52R
has opposite effects on IL-1/TLR-induced NFB and MAP ki-
nase activation and can in fact activate MAP kinases in the
absence of any other stimulus.
Activation of p38 by A52R Requires Interaction with TRAF6—
Activation of p38 by A52R could conceivably be because of its
ability to interact with either IRAK2 or TRAF6 (15). To deter-
mine whether this was the case, we began to generate trun-
cated versions of A52R to map the sites of interaction between
A52R and TRAF6 and IRAK2. A truncated version of A52R
lacking 46 amino acids at the C-terminal was constructed (Fig.
2A). This truncated A52R protein, here termed A52R, was
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detectable by the anti-A52R antibody and was expressed at
similar levels to A52R (Fig. 2, B and C). To determine whether
A52R was still capable of interacting with TRAF6 and/or
IRAK2, co-immunoprecipitations were carried out. A52R was
unable to form a complex with TRAF6 but retained its ability to
interact with IRAK2. A co-immunoprecipitation with anti-
TRAF6 antibody pulled down A52R with both endogenous
TRAF6 (Fig. 2B, top panel, lane 1) and overexpressed TRAF6
FIG. 2. A52R activates MAP kinases via the TRAF6 interaction. A, schematic representation of A52R and A52R. B and C, HEK 293T cells
were transfected with 4 g of TRAF6 (B) or 4 g of Myc-IRAK2 (C) and 4 g of A52R (left panel) or A52R (right panel) as indicated. After 24 h,
lysates were subjected to immunoprecipitation (IP) and subsequent immunoblotting (IB) with the indicated antibodies. Data are representative of
one experiment from a minimum of three separate experiments.D, HEK 293 cells were transfected with 100 ng of plasmid encoding pcDNA3.1 (EV)
or A52R or A52R, phPL-TK reporter gene, 0.25 ng of CHOP Gal4 fusion vector, or 0.25 ng of c-Jun Gal4 fusion vector and pFR luciferase reporter
plasmids, as described under “Materials and Methods.” After 24 h the cells were harvested and the reporter gene activity measured. Data are
expressed as mean -fold induction S.D. relative to control levels, for a representative experiment from a minimum of three separate experiments,
each performed in triplicate.
FIG. 1. A52R drives p38 MAP kinase activation. A, HEK 293 cells were transfected with increasing amounts (ng) of a plasmid encoding A52R
as indicated, the phRL-TK reporter gene, 0.25 ng of CHOP Gal4 fusion vector and pFR luciferase reporter plasmids as described under “Materials
and Methods.” B, HEK 293 cells stably expressing pcDNA 3.1, TLR3, or TLR4 were transfected with increasing amounts (ng) of A52R as indicated,
the phRL-TK reporter gene and the NFB reporter plasmid. Six hours prior to harvesting, the cells were stimulated with 100 ng/ml IL-1, 25 g/ml
poly(I:C), or 1 g/ml LPS as indicated, and luciferase gene activity was measured. C, HEK 293 cells were transfected with increasing amounts (10,
30, and 100 ng) of a plasmid encoding A52R, the phRL-TK reporter gene, 0.25 ng of CHOP Gal4 fusion vector, or 0.25 ng of c-Jun Gal4 fusion vector
and pFR luciferase and harvested 24 h later. Data are expressed as mean -fold induction  S.D. relative to control levels, for a representative
experiment from a minimum of three separate experiments, each performed in triplicate.
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(Fig. 2B, top panel, lane 3). In contrast, under the same condi-
tions A52R was not detected in complex with either endoge-
nous or overexpressed TRAF6 (Fig. 2B, top panel, lanes 4 and
6). However, a clear interaction between A52R and IRAK2
was observed (Fig. 2C). The ability of A52R and A52R to form
a complex with IRAK2 appeared equal (Fig. 2C, top panels,
compare lanes 3 and 6). Next, the ability of A52R to induce
MAP kinase activation was tested. Fig. 2D shows that in con-
trast to A52R, A52R failed to drive p38 and JNK activation.
Thus, the failure of A52R to activate p38 and JNK correlated
with its inability to interact with TRAF6, suggesting a role for
TRAF6 in the stimulatory effect of A52R on MAP kinases.
A52R Activates p38 via the TRAF Domain of TRAF6—We
next sought to examine more closely how the interaction be-
tween A52R and TRAF6 was responsible for the p38 MAP
kinase activation. Fig. 3A shows that consistent with previous
work (15), A52R interacted with the TRAF domain of TRAF6
(amino acids 289–522). The TRAF domain of TRAF6, here
termed TRAF6, has been reported to act as a dominant neg-
ative, inhibiting IL-1-induced p38 and JNK activation (22). We
therefore hypothesized that if the A52R-TRAF domain interac-
tion was important for A52R-induced p38 activation, overex-
pression of TRAF6 would sequester A52R and prevent p38
MAP kinase activation. To test this we examined p38 activa-
tion by Western blot analysis in HEK 293 cells using a phos-
pho-specific p38 antibody. Fig. 3B shows that transfection of
cells with TRAF6 alone had no effect on levels of phospho-p38
(upper panel, lane 2). Consistent with the reporter gene based
assay (Fig. 1), overexpression of A52R led to an increase in
phospho-p38 (Fig. 3B, upper panel, compare lane 3 to lane 1),
whereas A52R expression had no effect on phospho-p38 (not
shown). Co-expression of TRAF6 with A52R completely inhib-
ited A52R-mediated p38 activation (Fig. 3B, upper panel, lane
4). As a control, A52R was shown to have no effect on IB
protein levels (Fig. 3B, third panel), and similarly did not lead
to an increase in IB phosphorylation (not shown). Inhibition
of p38 MAP kinase activation by overexpression of TRAF6
was likely because of TRAF6 sequestering A52R and prevent-
ing its interaction with endogenous TRAF6. Fig. 3C shows this
to be the case because the presence of overexpressed TRAF6
inhibited the interaction of A52R with endogenous TRAF6
(compare lanes 4 and 2). Thus A52R activates p38 by engaging
the TRAF domain of TRAF6.
A52R Enhances TLR-induced IL-10 Induction While Inhib-
iting NFB-dependent Genes—Previous studies have shown
that LPS-induced IL-10 production is p38 dependent (23, 24).
Therefore, we wondered whether A52R would have an effect on
IL-10 induction. We first examined the effect of A52R on the
IL-10 promoter using a reporter gene assay. Interestingly,
A52R was capable of driving the IL-10 promoter in a dose-de-
pendent manner (Fig. 4A). In contrast, A52R expression did not
affect the basal activity of a range of NFB-dependent promot-
ers, including IL-8, RANTES, and interferon- (not shown). To
examine whether the induction of the IL-10 promoter was
TRAF6-dependent, we next assessed the ability of TRAF6 to
inhibit A52R-mediated IL-10 induction. Fig. 4B shows that a
single dose of TRAF6 was capable of negating the stimulatory
effect of A52R on the IL-10 promoter. In addition, A52R failed
to activate the IL-10 reporter in TRAF6/ murine embryonic
fibroblasts (MEFs). In the absence of TRAF6, the ability of
A52R to drive the IL-10 promoter was abolished compared with
a 3-fold induction in normal MEFs (Fig. 4C), thus implicating
TRAF6 in the activation of the IL-10 promoter by A52R. We
next used the murine macrophage cell line RAW 264.7 to ana-
lyze the effect of A52R-induced IL-10 protein production. The
p38 inhibitor SB203580 has previously been shown to inhibit
LPS/TLR4-induced IL-10 production in human peripheral
blood mononuclear cells (23) and in the human monocyte cell
line THP-1 (24). Consistent with this, here SB203580 inhibited
LPS-induced IL-10 production (Fig. 5A, right panel). Expres-
sion of A52R alone did not lead to IL-10 production in unstimu-
lated cells (Fig. 5A, left panel). However, expression of A52R
strongly enhanced LPS-induced IL-10 production (Fig. 5A, left
panel). This is suggestive of a potent effect on TLR-induced
IL-10 production given that only a small fraction (3% on aver-
age, not shown) of the RAW 264.7 cells stimulated by LPS to
release IL-10 would be expected to be expressing A52R in this
FIG. 3. A52R activates p38 via the TRAF domain of TRAF6. A,
HEK 293T cells were transfected with 4 g of A52R and 4 g of
FLAG-TRAF6 as indicated. After 24 h lysates were subjected to im-
munoprecipitation (IP) and subsequent SDS-PAGE and immunoblot-
ting (IB) with the indicated antibodies. Whole cell lysates were ana-
lyzed for expression of A52R. B, HEK 293 cells were seeded into a 6-well
plate. 24 h later the cells were transfected with 1150 ng of expression
plasmids TRAF6 and/or A52R as indicated. Cells were harvested 24 h
later, and lysates were subjected to SDS-PAGE and immunoblotting
with antibodies to the indicated protein. C, HEK 293 cells were trans-
fected with 0.5 g of A52R and 7.5 g of TRAF6 as indicated. After
24 h, lysates were subjected to immunoprecipitation and subsequent
immunoblotting with the indicated antibodies. Whole cell lysates were
analyzed for expression of A52R. Data are representative of one exper-
iment from two separate experiments.
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transient transfection system. The fact that A52R failed to
drive the IL-10 promoter in TRAF6/ MEFs suggested that
the TRAF6-A52R interaction was critical for the effect of A52R
on IL-10 production. This conclusion prompted us to examine
the role of TRAF6 on LPS-induced IL-10 production. Consistent
with the effect of A52R on LPS-induced IL-10, ectopic expres-
sion of TRAF6 enhanced (Fig. 5B, left panel), whereas TRAF6
inhibited (Fig. 5B, right panel), LPS-induced IL-10 production.
Next we sought to compare the effect of A52R on IL-10 induc-
tion to its effects on two NFB-dependent genes, the chemo-
kines IL-8 (25) and RANTES (26). Stimulation of HEK-TLR4
cells with LPS led to IL-8 production, whereas stimulation of
HEK-TLR3 cells with poly(I:C) led to RANTES production (Fig.
5C). In both cases transient transfection with A52R inhibited
chemokine production in a dose-dependent manner (Fig. 5C).
Thus A52R differentially modulates TLR-induced gene expres-
sion, by potentiating the p38-dependent gene IL-10, while in-
hibiting the NFB-dependent genes IL-8 and RANTES.
DISCUSSION
In this report we investigated the effect of the VV protein
A52R on MAP kinase activation and LPS-induced IL-10 pro-
duction. We showed that A52R expression could activate both
p38 and JNK MAP kinases. Furthermore, we showed that
A52R dramatically enhanced TLR4-induced IL-10 production,
which is known to be p38-dependent. In contrast, inhibition of
the TLR-induced NFB-dependent chemokines IL-8 and RAN-
TES by A52R was observed. The fact that A52R differentially
modulates TLR signaling reveals a further layer of complexity
in the viral subversion of TLRs.
The ability of A52R to activate p38 was dependent on
TRAF6. The fact that A52R, which could not form a complex
with TRAF6 (Fig. 2B), failed to activate p38 and JNK (Fig. 2D)
suggests that TRAF6 is crucial for mediating p38 and JNK
activation by A52R (Fig. 1C). Furthermore, overexpression of
the TRAF domain of TRAF6, which A52R interacts with,
blocked the ability of A52R to activate p38, by inhibiting the
interaction of A52R with endogenous TRAF6 (Fig. 3C). The
TRAF domain of TRAF6 is responsible for mediating oligomer-
ization of TRAF6 (22). This facilitates the interaction of TRAF6
with TRAF6-regulated IB kinase activator 1, a dimeric ubiq-
uitin-conjugating enzyme complex composed of Ubc13 and
Uve1A (27). This interaction causes a novel form of polyubiq-
uitination involving Lys63 of ubiquitin to occur. TRAF6 is ubiq-
uitinated and TAK1 is activated, which in turn phosphorylates
MAP kinase kinase 6 in the JNK-p38 kinase pathways (27). In
the absence of any upstream activation, enforced oligomeriza-
tion of TRAF6 leads to MAP kinase activation (22). It remains
to be determined whether A52R can modulate TRAF6 ubiquiti-
nation, oligomerization, or TAK1 activation. Previously it was
thought that A52R inhibited NFB activation by disrupting the
formation of a TRAF6-TAK1-TAK1-binding protein 1 complex
(15). However, NFB inhibition by A52R is more likely to be
because of its ability to interact with IRAK2 (Fig. 2C and Ref.
15), because A52R, which only interacted with IRAK2 and not
TRAF6 (Fig. 2, B and C), was still capable of inhibiting TLR-
induced NFB activation (data not shown).
McCoy et al. (28) recently showed that a peptide derived from
11 amino acids of A52R was capable of inhibiting cytokine
secretion in response to TLR activation. This study is consist-
ent with our findings, because in Fig. 5C we show that full-
length A52R can also inhibit TLR-induced cytokine and che-
mokine production. McCoy et al. (28) speculate, and show some
data to suggest, that the inhibitory effects they observe are
because of an inhibition of NFB. Importantly, the peptide with
this inhibitory capacity maps to a region in A52R, suggesting
that the peptide is likely to be mediating its effects via IRAK2,
leading to NFB inhibition.
The effect of A52R on the activation of the MAP kinases p38
and JNK is consistent with the emerging theme that viral
proteins engage host TRAF molecules to modulate signaling
pathways. For example, the non-structural 5A (NS5A) protein
of hepatitis C virus interacts with the TRAF domain of TRAF2
and can potentiate TNF-induced JNK activation (29). Another
viral protein, VP4 from rotaviruses, also interacts with TRAF2.
However, this protein has opposite effects to A52R in that it
activates NFB and inhibits JNK activation (30). In addition,
similar to A52R, the oncogenic latent membrane protein 1 from
Epstein-Barr virus has been shown to induce p38 MAP kinase
through a TRAF6-dependent mechanism (31). Similar to our
findings (Fig. 3B) overexpression of a dominant negative form
of TRAF6 entirely blocked p38 MAP kinase induction by latent
membrane protein 1 (31).
The ability of A52R to activate p38, together with its known
inhibitory effect on NFB activation were shown to translate
into effects on gene induction by TLRs. LPS-induced IL-10
(which is a known to be p38-dependent) was enhanced in the
presence of A52R (Fig. 5A), whereas TLR-induced NFB-de-
pendent chemokine production was inhibited (Fig. 5C). The
effect of A52R on LPS-induced IL-10 was likely to be at the
level of the promoter, because A52R expression led to activa-
tion of an IL-10 promoter (Fig. 4A). However, A52R expression
did not lead to IL-10 protein in the absence of LPS (Fig. 5A, left
FIG. 4. A52R drives the IL-10 promoter in a TRAF6-dependent
manner. A and B, HEK 293 cells were seeded into a 96-well plate and
transfected 24 h later with the IL-10 promoter luciferase reporter
plasmid, phRL-TK, and increasing amounts of A52R (10, 30, and 100
ng) (A) or 30 ng of A52R in the presence of 30 ng of a plasmid encoding
TRAF6 as indicated (B). C, TRAF6/MEFs or TRAF6/MEFs were
seeded into a 96-well plate and transfected 24 h later with the IL-10
promoter luciferase reporter plasmid, phRL-TK, and 100 ng of A52R.
After 24 h the cells were harvested and the reporter gene activity
measured. Data are expressed as mean fold -induction  S.D. relative
to control levels, for a representative experiment from a minimum of
three separate experiments, each performed in triplicate.
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panel), suggesting that induction of IL-10 promoter by A52R
was not sufficient to lead to protein expression. Rather, A52R
may synergize with LPS at the level of the IL-10 promoter
(presumably in a p38-dependent fashion), leading to enhanced
IL-10 production when the TLR4 pathway is fully activated.
TRAF6 was clearly shown to have a role in the synergistic
effect, because TRAF6, which inhibited the interaction of
A52R with endogenous TRAF6 (Fig. 3C), blocked IL-10 pro-
moter induction by A52R (Fig. 4B), whereas A52R could not
induce the IL-10 promoter in TRAF6/ MEFs (Fig. 4C). Fur-
thermore, ectopic expression of TRAF6 led to a similar effect on
IL-10 protein in the presence of LPS (Fig. 5B, left panel) as seen
for A52R. Interestingly, IRAK1 has also recently been shown to
be critically involved in LPS-induced IL-10 production (32).
Furthermore, latent membrane protein 1 from Epstein-Barr
virus, which as mentioned can interact with TRAF6 and poten-
tiate p38, can induce IL-10 production (31, 33). The enhance-
ment of IL-10 production by A52R (and indeed TRAF6) may
also have a post-translational component because IL-10 mRNA
contains destabilizing AU repeats in its 3-untranslated region
(34). It is known that p38 activation leads to stabilization of
cytokine mRNA containing these repeats (35).
IL-10 is a pleiotropic cytokine that inhibits inflammatory
and cell-mediated immune responses (3). TLR-induced IL-10
has been shown to have a role in the generation of T regulatory
cells and to lead to the inhibition of Th-1 responses (36–38).
TLR-mediated anti-inflammatory signals are beneficial after
the elimination of pathogens; however, they can induce dan-
gerous immunosuppressive mechanisms if activated too early
during a severe infection. Recently it has become clear that
TLR-induced IL-10 represents an important target of immune
subversion for some pathogens. For example, the Yersinia vir-
ulence factor LcrV interacts with TLR2 leading to immunosup-
pression by induction of IL-10 (39). TLR2/ mice (39) and
IL-10/ mice (40) are less susceptible to oral Yersinia entero-
colitica infection than wild type controls. The fungus Candida
albicans has been shown to trigger immunosuppression
through TLR2-induced IL-10 and subsequent survival of T
regulatory cells (37). In addition, immune escape of mouse
mammary tumor virus, which leads to persistent infection, has
been shown to be dependent on TLR4-triggered production of
IL-10 (36). Therefore the enhancement of TLR4-induced IL-10
production by A52R may represent a vaccinia immune subver-
sion mechanism. Unlike other viruses such as Epstein-Barr
virus (41) and poxvirus Orf (42), VV does not encode an IL-10
homologue. However, VV replication has been shown to be
impaired in IL-10/ mice (43). Another study showed that VV
infection induced IL-10 in human monocytes, with a more
FIG. 5. Differential effects of A52R on TLR-dependent gene induction. A, murine macrophage RAW 264.7 cells were transfected with 180
ng of plasmid encoding A52R, 24 h prior to stimulation with 1 g/ml LPS (left panel). Two hours after stimulation with LPS, 10 M SB203580 was
added (right panel). Twenty-four hours after stimulation supernatants were harvested and assayed for IL-10 by enzyme-linked immunosorbent
assay. Data are expressed as picograms/ml  S.D. relative to control levels, for a representative experiment from a minimum of three separate
experiments, each performed in triplicate. B, RAW 264.7 cells were transfected with 180 ng of plasmid encoding TRAF6 (left panel) or TRAF 6
(right panel) 24 h prior to stimulation with 1 g/ml LPS. Twenty-four hours after stimulation, supernatants were harvested and assayed for IL-10
by enzyme-linked immunosorbent assay. C, HEK-TLR4 (left panel) or HEK-TLR3 (right panel) cells were transfected with the indicated amounts
of a plasmid encoding A52R 24 h prior to stimulation with 1 g/ml LPS (left panel) or 25 g/ml poly(I:C) (right panel). Twenty-four hours after
stimulation, supernatants were harvested and assayed for IL-8 and RANTES by enzyme-linked immunosorbent assay. Data are expressed as
picograms/ml  S.D. relative to control levels, for a representative experiment from two experiments, each performed in triplicate.
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significant increase in IL-10 expression observed following LPS
treatment (44). Therefore, the ability of A52R to enhance TLR-
induced IL-10 production may be contributing to the IL-10
production observed in infected human monocytes.
To date TLR2, -3, -4, -7, -8, and -9 have been shown to be
activated by viral proteins and nucleic acids (8–12, 45–48).
However, no TLR has yet been shown to recognize VV. Never-
theless, VV encodes other proteins that have been shown to
target the IL-1R-TLR superfamily; these are A46R and N1L
(13, 14). A46R is a viral TIR domain-containing protein that
interacts with TIR adaptor proteins leading to inhibition of
IL-1R/TLR signaling (13, 16), whereas N1L has been shown to
suppress NFB activation by IL-1R-TLRs by targeting the IKK
complex (14). However, the ability to enhance TLR-induced
IL-10 is unique to A52R, because overexpression of neither
A46R nor N1L resulted in an increase (or decrease) in TLR-
stimulated IL-10 production (not shown). Furthermore, A52R,
A46R, and N1L are not functionally redundant because a single
deletion of each gene affected virus virulence (15, 16, 49).
This study sheds further light on how VV interacts with the
TLR system, and reveals that A52R is a multifunctional VV
protein that not only inhibits TLR-mediated NFB activation
(13, 15) and NFB-dependent genes, but can also, via TRAF6,
activate p38 MAP kinase and subsequently potentiate TLR-
induced IL-10. Both of these activities of A52R are likely to
contribute to its role in virulence (15).
REFERENCES
1. Akira, S., and Takeda, K. (2004) Nat. Rev. Immunol. 4, 499–511
2. Yamamoto, M., Takeda, K., and Akira, S. (2004) Mol. Immunol. 40, 861–868
3. Moore, K. W., de Waal Malefyt, R., Coffman, R. L., and O’Garra, A. (2001)
Annu. Rev. Immunol. 19, 683–765
4. Janssens, S., and Beyaert, R. (2002) Trends Biochem. Sci. 27, 474–482
5. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and
Akira, S. (2002) J. Immunol. 169, 6668–6672
6. Hoebe, K., Du, X., Georgel, P., Janssen, E., Tabeta, K., Kim, S. O., Goode, J.,
Lin, P., Mann, N., Mudd, S., Crozat, K., Sovath, S., Han, J., and Beutler, B.
(2003) Nature 424, 743–748
7. Akira, S., Yamamoto, M., and Takeda, K. (2003) Biochem. Soc. Trans. 31,
637–642
8. Alexopoulou, L., Holt, A. C., Medzhitov, R., and Flavell, R. A. (2001) Nature
413, 732–738
9. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., and Reis e Sousa, C. (2004)
Science 303, 1529–1531
10. Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W.,
Iwasaki, A., and Flavell, R. A. (2004) Proc. Natl. Acad. Sci. U. S. A. 101,
5598–5603
11. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S.,
Lipford, G., Wagner, H., and Bauer, S. (2004) Science 303, 1526–1529
12. Krug, A., Luker, G. D., Barchet, W., Leib, D. A., Akira, S., and Colonna, M.
(2004) Blood 103, 1433–1437
13. Bowie, A., Kiss-Toth, E., Symons, J. A., Smith, G. L., Dower, S. K., and O’Neill,
L. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10162–10167
14. DiPerna, G., Stack, J., Bowie, A. G., Boyd, A., Kotwal, G., Zhang, Z., Arvikar,
S., Latz, E., Fitzgerald, K. A., andMarshall, W. L. (2004) J. Biol. Chem. 279,
36570–36578
15. Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W.,
Smith, G. L., Bowie, A., and O’Neill, L. A. (2003) J. Exp. Med. 197, 343–351
16. Stack, J., Haga, I. R., Schroder, M., Bartlett, N. W., Maloney, G., Reading,
P. C., Fitzgerald, K. A., Smith, G. L., and Bowie, A. G. (2005) J. Exp. Med.
201, 1007–1018
17. Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J., and Ploegh, H. L.
(2000) Annu. Rev. Immunol. 18, 861–926
18. Moss, B. (2001) in Fields Virology (Knipe, D. M., Griffin, D. E., Chanock, R. M.,
Lamb, R. A., Lamb, M. A., Roizman, B., and Straus, S. E., eds) Vol. 2, pp.
2849–2883, Lippincott-Raven, New York
19. Muzio, M., Ni, J., Feng, P., and Dixit, V. M. (1997) Science 278, 1612–1615
20. Benkhart, E. M., Siedlar, M., Wedel, A., Werner, T., and Ziegler-Heitbrock,
H. W. (2000) J. Immunol. 165, 1612–1617
21. Fitzgerald, K. A., Rowe, D. C., Barnes, B. J., Caffrey, D. R., Visintin, A., Latz,
E., Monks, B., Pitha, P. M., and Golenbock, D. T. (2003) J. Exp. Med. 198,
1043–1055
22. Baud, V., Liu, Z. G., Bennett, B., Suzuki, N., Xia, Y., and Karin, M. (1999)
Genes Dev. 13, 1297–1308
23. Foey, A. D., Parry, S. L., Williams, L. M., Feldmann, M., Foxwell, B. M., and
Brennan, F. M. (1998) J. Immunol. 160, 920–928
24. Ma, W., Lim, W., Gee, K., Aucoin, S., Nandan, D., Kozlowski, M., Diaz-Mitoma,
F., and Kumar, A. (2001) J. Biol. Chem. 276, 13664–13674
25. Jung, Y. D., Fan, F., McConkey, D. J., Jean, M. E., Liu, W., Reinmuth, N.,
Stoeltzing, O., Ahmad, S. A., Parikh, A. A., Mukaida, N., and Ellis, L. M.
(2002) Cytokine 18, 206–213
26. Genin, P., Algarte, M., Roof, P., Lin, R., and Hiscott, J. (2000) J. Immunol. 164,
5352–5361
27. Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., and Chen, Z. J. (2001)
Nature 412, 346–351
28. McCoy, S. L., Kurtz, S. E., Macarthur, C. J., Trune, D. R., and Hefeneider,
S. H. (2005) J. Immunol. 174, 3006–3014
29. Park, K. J., Choi, S. H., Choi, D. H., Park, J. M., Yie, S. W., Lee, S. Y., and
Hwang, S. B. (2003) J. Biol. Chem. 278, 30711–30718
30. LaMonica, R., Kocer, S. S., Nazarova, J., Dowling, W., Geimonen, E., Shaw,
R. D., and Mackow, E. R. (2001) J. Biol. Chem. 276, 19889–19896
31. Schultheiss, U., Puschner, S., Kremmer, E., Mak, T. W., Engelmann, H.,
Hammerschmidt, W., and Kieser, A. (2001) EMBO J. 20, 5678–5691
32. Huang, Y. L. T., Sane, D. C., and Li, L. (2004) J. Biol. Chem. 279, 51697–51703
33. Vockerodt, M., Haier, B., Buttgereit, P., Tesch, H., and Kube, D. (2001) Virol-
ogy 280, 183–198
34. Powell, M. J., Thompson, S. A., Tone, Y., Waldmann, H., and Tone, M. (2000)
J. Immunol. 165, 292–296
35. Dean, J. L., Sully, G., Clark, A. R., and Saklatvala, J. (2004) Cell Signal. 16,
1113–1121
36. Netea, M. G., Van der Meer, J. W., and Kullberg, B. J. (2004) Trends Microbiol.
12, 484–488
37. Netea, M. G., Sutmuller, R., Hermann, C., Van der Graaf, C. A., Van der Meer,
J. W., van Krieken, J. H., Hartung, T., Adema, G., and Kullberg, B. J. (2004)
J. Immunol. 172, 3712–3718
38. Higgins, S. C., Lavelle, E. C., McCann, C., Keogh, B., McNeela, E., Byrne, P.,
O’Gorman, B., Jarnicki, A., McGuirk, P., and Mills, K. H. (2003) J. Immu-
nol. 171, 3119–3127
39. Sing, A., Rost, D., Tvardovskaia, N., Roggenkamp, A., Wiedemann, A., Kir-
schning, C. J., Aepfelbacher, M., and Heesemann, J. (2002) J. Exp. Med.
196, 1017–1024
40. Sing, A., Roggenkamp, A., Geiger, A. M., and Heesemann, J. (2002) J. Immu-
nol. 168, 1315–1321
41. Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., and
Mosmann, T. R. (1990) Science 248, 1230–1234
42. Fleming, S. B., McCaughan, C. A., Andrews, A. E., Nash, A. D., and Mercer,
A. A. (1997) J. Virol. 71, 4857–4861
43. van Den Broek, M., Bachmann, M. F., Kohler, G., Barner, M., Escher, R.,
Zinkernagel, R., and Kopf, M. (2000) J. Immunol. 164, 371–378
44. Slezak, K., Guzik, K., and Rokita, H. (2000) Cytokine 12, 900–908
45. Bieback, K., Lien, E., Klagge, I. M., Avota, E., Schneider-Schaulies, J., Duprex,
W. P., Wagner, H., Kirschning, C. J., Ter Meulen, V., and Schneider-
Schaulies, S. (2002) J. Virol. 76, 8729–8736
46. Compton, T., Kurt-Jones, E. A., Boehme, K. W., Belko, J., Latz, E., Golenbock,
D. T., and Finberg, R. W. (2003) J. Virol. 77, 4588–4596
47. Haynes, L. M., Moore, D. D., Kurt-Jones, E. A., Finberg, R. W., Anderson, L. J.,
and Tripp, R. A. (2001) J. Virol. 75, 10730–10737
48. Rassa, J. C., and Ross, S. R. (2003) Microbes Infect. 5, 961–968
49. Bartlett, N., Symons, J. A., Tscharke, D. C., and Smith, G. L. (2002) J. Gen.
Virol. 83, 1965–1976
Vaccinia Virus Protein A52R Differentially Modulates TLR Signalling30844
 by guest on M
arch 24, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Geraldine Maloney, Martina Schröder and Andrew G. Bowie
Potentiates Lipopolysaccharide-induced Interleukin-10
Vaccinia Virus Protein A52R Activates p38 Mitogen-activated Protein Kinase and
doi: 10.1074/jbc.M501917200 originally published online July 5, 2005
2005, 280:30838-30844.J. Biol. Chem. 
  
 10.1074/jbc.M501917200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/280/35/30838.full.html#ref-list-1
This article cites 49 references, 32 of which can be accessed free at
 by guest on M
arch 24, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
